Advertisement

 

 

Dabrafenib plus Trametinib Is Active in BRAF(V600E) Anaplastic Thyroid Cancer.

Dabrafenib plus Trametinib Is Active in BRAF(V600E) Anaplastic Thyroid Cancer.
Advertisement

Cancer discovery 2017 11 10() doi 10.1158/2159-8290.CD-RW2017-212

Abstract

Dual BRAF/MEK inhibition achieves responses in 69% of BRAFV(600E) anaplastic thyroid cancers (ATC).

Submit a Comment

Your email address will not be published. Required fields are marked *

three × 4 =

[ HIDE/SHOW ]